Glancy Prongay & Murray Commences Investigation on Behalf of Flower Foods, Inc. Investors
Get Alerts FLO Hot Sheet
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 10.7%
Revenue Growth %: 0.0%
Join SI Premium – FREE
LOS ANGELES--(BUSINESS WIRE)-- Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of investors of Flower Foods, Inc. ("Flower Foods" or the "Company") (NYSE: FLO). The investigation concerns whether the Company’s and its officers potentially violated securities laws by misleading investors regarding its compliance with U.S. Department of Labor regulations.
On August 10, 2016, the Company announced that, “the U.S. Department of Labor notified the Company that it has been scheduled for a compliance review under the Fair Labor Standards Act.” On this news the Company’s shares fell over $1.30 per share, or over 7%, during intraday trading on August 10, 2016.
If you purchased Flower Foods securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to [email protected], or visit our website at http://www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160810005929/en/
Glancy Prongay & Murray LLP, Los Angeles
Lesley Portnoy,
310-201-9150 or 888-773-9224
[email protected]
www.glancylaw.com
Source: Glancy Prongay & Murray LLP
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- CGA.vitaslim Announces Mission to Help 5,000 Adults Combat the "Three Highs" and Reclaim Their Health and Wealth in Hong Kong
- Orion Pharma’s ODM-212 Granted Orphan Designation for the Treatment of Malignant Mesothelioma by the European Commission
- Omnicom Launches Acxiom Fan Graph to Give Brands a More Complete View of Sports Fandom
Create E-mail Alert Related Categories
Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share